Status:
NOT_YET_RECRUITING
Physician- and Patient-based Barriers to NGS Testing
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
Pfizer
Conditions:
Metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provi...
Detailed Description
Next-generation sequencing is recommended by national guidelines in metastatic prostate cancer to inform prognosis, treatment decisions, and eligibility for clinical trials. However, rates are low nat...
Eligibility Criteria
Inclusion
- men diagnosed with metastatic prostate cancer
- seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026
Exclusion
- \- Patients who have already had NGS testing performed.
Key Trial Info
Start Date :
January 15 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT07209176
Start Date
January 15 2026
End Date
September 1 2027
Last Update
January 7 2026
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.